Clinical trials: TACE, completed
Hepatocellular Carcinoma
Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma
The purpose of this study is to evaluate efficacy, safety, and patient reported outcomes (PRO) of different regimens of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
- Trial name
- TACEforHCC (NCT00493402)
- Testing
- Transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 365 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).
- Trial name
- TACE (NCT00539253)
- Testing
- gadobenate dimeglumine (MultiHance)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carcinoma, Hepatocellular
Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Patients with liver tumor burden that exceeds Milan criteria are considered to receive one of the following locoregional treatments: transarterial chemoembolization (TACE), radiofrequency ablation (RFA), percutaneous ethanol…
- Trial name
- NCT00857805
- Testing
- Transarterial Chemoembolization, Proton Beam Radiotherapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Loma Linda University
Carcinoma, Hepatocellular
Adjuvant TACE to Reduce the HCC Recurrence After Resection
Hepatocellular carcinoma (HCC) is the sixth most common malignancies worldwide and the second leading cause of cancer-related death.
- Trial name
- NCT02788526
- Testing
- Adjuvant TACE, Follow-up
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment
The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib
- Trial name
- BRISK PS (NCT00825955)
- Testing
- Brivanib, Best Supportive Care
- Where
- 113 sites in United States, Argentina and 17 more
- Volunteers
- 587 people
- Sponsor
- Bristol-Myers Squibb
Liver Cancer
Radiofrequency-assisted Liver Resection in Intractable Liver Cancer
In this retrospective study, the investigators assessed the application of radiofrequency-assisted liver resection in intractable liver cancer resection, and plan to analysis the different factors.
- Trial name
- NCT04413526
- Testing
- radiofrequency, TACE, TACE+radiofrequency
- Where
- China
- Volunteers
- 199 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Hepatocellular Carcinoma
AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)
Hepatocellular carcinoma (HCC) is one of the tumors with an increasing incidence worldwide. Often treatment possibilities are limited and only palliative treatment such as a transarterial chemoembolisation (TACE) is possible.
- Trial name
- NCT01360255
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Freiburg
Hepatocellular Carcinoma
Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation
Hepatocellular carcinoma (HCC) can present itself in many forms (size, number of lesions) for the treatment of which a therapeutic panel can be elaborated and layered.
- Trial name
- CELPerCutCHC (NCT04813861)
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Central Hospital, Nancy, France
Hepatocellular Carcinoma, Radioembolization
Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most-common cancer worldwide and the second most-common cause of cancer mortality. Liver resection is the first-line curative treatment for huge HCC.
- Trial name
- NCT02724436
- Testing
- TACE, radioembolization with Y-90
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE.
- Trial name
- NCT05121571
- Testing
- HAIC, Sorafenib
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy
A glycyrrhizin-containing product, Stronger Neo-Minophagen C TM (SNMC; Minophagen Pharmaceutical Co.Ltd.,Tokyo,Japan),is widely used in Japan for suppression of hepatitis activity and for prevention of disease progression in…
- Trial name
- NCT04015245
- Testing
- Stronger Neo-Minophagen C
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chimei Medical Center
Biliary Tract Neoplasms, Liver Cancer
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
BACKGROUND: Various tumor ablative procedures and techniques have been shown to result in immunogenic cell death and induction of a peripheral immune response.
- Conditions
- Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT02821754
- Testing
- Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Hepatocellular
Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib
This study will collect data of patients who are treated with TACE followed by sorafenib for hepatocellular carcinoma (HCC) or patients without Sorafenib after TACE.
- Trial name
- OPTIMIS (NCT01933945)
- Testing
- TACE (transarterial chemoembolization), Sorafenib (Nexavar, BAY43-9006)
- Where
- 31 sites in Austria, Brazil and 29 more
- Volunteers
- 1,676 people
- Sponsor
- Bayer
Hepatocellular Carcinoma (HCC)
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity of peri-interventional treatment with the anti-PD1 antibody pembrolizumab in HCC patients who are candidates for local…
- Trial name
- NCT03753659
- Testing
- Pembrolizumab, Radio Frequency Ablation (RFA), Microwave Ablation (MWA)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Liver Cancer
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00956930
- Testing
- yttrium Y 90 glass microspheres, Doxorubicin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Northwestern University
Intrahepatic Cholangiocarcinoma
A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC
At present, for advanced Intrahepatic Cholangiocarcinoma（ICC）, the effect of single treatment is not good.So far, superselective drug-eluting bead transarterial chemoembolization（DEB-TACE） is a good method for the treatment of…
- Trial name
- CCGLC-005 (NCT05236699)
- Testing
- DEB-TACE combined with Surufatinib and Camrelizumab
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT
Hepatocellular carcinoma (HCC) is characterized with vascular invasion, particularly of the portal vein, resulting in portal vein tumor thrombus (PVTT) in 10%-40% of HCC patients at the time of HCC diagnosis.
- Trial name
- NCT05535998
- Testing
- TACE-HAIC, TACE, Targeted therapy
- Where
- China
- Volunteers
- 743 people
- Sponsor
- Yunfei Yuan
Carcinoma, Hepatocellular, Neoplasms, Liver
Radiofrequency Versus Laser Ablation for Hepatocellular Carcinoma
The purpose of this study is to prospectively compare percutaneous radiofrequency ablation (RFA) versus percutaneous laser ablation (LA) for the treatment of small hepatocellular carcinoma in patients with cirrhosis.
- Trial name
- NCT01096914
- Testing
- percutaneous radiofrequency ablation, percutaneous laser ablation
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Cardarelli Hospital
Liver Metastasis Colon Cancer
TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens
Liver metastasis is the main reason that affects the survival rates of patients with colorectal cancer (CRLM), and is also the main cause of death of those patients.
- Trial name
- DREAM (NCT06071052)
- Testing
- TACE and HAIC Combined With Regorafenib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC
This is an observational, multicenter, single arm, prospective study to evaluate safety and tolerability of selective and ultraselective drug eluting beads transcatheter intraarterial chemoembolization (DEB-TACE) with up to 3 ml…
- Trial name
- NCT02670122
- Testing
- DEB-TACE
- Where
- Spain
- Volunteers
- 131 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz